Saltar al contenido principal
Elsevier

Breaking Tolerance to Pancreatic Cancer Unresponsiveness to Chemotherapy

  • 1 Edición, Volumen 5 - 26 de febrero de 2019
  • Última edición
  • Editores: Ganji Purnachandra Nagaraju, Benjamin Bonavida
  • Idioma: Inglés

Breaking Tolerance to Pancreatic Cancer Unresponsiveness to Chemotherapy edited by Dr. Nagaraju, PhD., DSc. focuses on overriding the resistance from chemotherapeutic drugs wit… Leer más

Descripción

Breaking Tolerance to Pancreatic Cancer Unresponsiveness to Chemotherapy edited by Dr. Nagaraju, PhD., DSc. focuses on overriding the resistance from chemotherapeutic drugs with a broader range of treatment options. It particularly focuses on stroma, tumor microenvironment, stem cells, stellate cells, transcription factors, growth factors, and important signaling pathways. This volume discusses topics such as pancreatic cancer biology, current therapeutic options, EMT, chemotherapy resistance mechanisms, and genetic manipulations and natural products to enhance the sensitivity of pancreatic cancer to chemotherapy. Additionally, it discusses small targeted molecules and pancreatic cancer trials, and nanotechnology-based drug delivery.Breaking Tolerance to Pancreatic Cancer Unresponsiveness to Chemotherapy is a valuable source for researchers and advanced students in cancer and oncology as well as clinicians and medical students who are interested in learning more about ways to break pancreatic cancer resistance to chemotherapy.

Puntos claves

  • Modulates the biologic properties of stroma in pancreatic cancer by targeting the several chemotherapy resistance mechanisms to impede their malignant property by introducing new strategies and drugs
  • Provides information about on-going research as well as clinical data on pancreatic cancer and detailed descriptions about therapeutic options for easy understanding
  • Utilizes full color figures to help the understanding of the content and tables for easy comparison of information as well as quick access to it

De interès para

Researchers and advanced students in cancer and oncology, clinicians and medical students

Índice

1. Overview of Pancreatic Cancer Biology2. Chemoresistance in Pancreatic Cancer: Emphasis on Age and Gender3. EMT Contributes to Chemoresistance in Pancreatic Cancer4. Pancreatic Cancer Resistance to Gemcitabine5. Pancreatic Cancer and Possible Therapeutic Options6. Curcumin and Genistein Enhances the Sensitivity of Pancreatic Cancer to Chemotherapy7. Terpenoids as Potential Targeted Therapeutics of Pancreatic Cancer: Current Advances and Future Directions8. Small Molecules and Pancreatic Cancer Trials and Troubles9. Targeting the Epigenome as a Therapeutic Strategy for Pancreatic Tumors - DNA and Histone Modifying Enzymes10. Are Nanocarriers Effective for the Diagnosis and Treatment of Pancreatic Cancer?11. Molecular Markers for Treatment Response and Toxicity of Gemcitabine

Detalles del producto

  • Edición: 1
  • Última edición
  • Volumen: 5
  • Publicado: 8 de marzo de 2019
  • Idioma: Inglés

Sobre los editores

GN

Ganji Purnachandra Nagaraju

Dr. Nagaraju obtained his MSc and his PhD, both in Biotechnology, from Sri Venkateswara University in Tirupati, Andhra Pradesh, India. He received his DSc from Berhampur University in Berhampur, Odisha, India. Dr. Nagaraju’s research focuses on translational projects related to gastrointestinal malignancies. He has published over 100 research papers in highly reputed international journals and has presented more than 50 abstracts at various national and international conferences. Dr. Nagaraju is author and editor of several published books in Elsevier and Springer Nature. He serves as editorial board member of several internationally recognized academic journals. Dr. Nagaraju has received several international awards including FAACC. He also holds memberships with the Association of Scientists of Indian Origin in America (ASIOA), the Society for Integrative and Comparative Biology (SICB), The Science Advisory Board, The RNA Society, The American Association for Clinical Chemistry (AACC) and the American Association of Cancer Research (AACR).
Afiliaciones y experiencia
Assistant Professor, School of Medicine, Division of Hematology and Oncology, University of Alabama, Birmingham, AL, USA

BB

Benjamin Bonavida

Dr Bonavida has vast expertise and various reported publications in the field of tumor cell sensitization to chemotherapy (a total of greater than 500 publications) and in particular the novel role of Nitric Oxide (NO) donors in chemo-sensitization and reversal of drug resistance. In addition, he was the first scientist to co-organize an international meeting on the topic (First International Workshop on NO and Cancer, 2005).

Afiliaciones y experiencia
Professor, Department of Microbiology, Immunology and Molecular Genetics, David Geffen School of Medicine, University of California, USA

Ver libro en ScienceDirect

Lee Breaking Tolerance to Pancreatic Cancer Unresponsiveness to Chemotherapy en ScienceDirect